Drug Trial Radar · NCT05002569
A Study to Assess Adjuvant Immunotherapy With Nivolumab Plus Relatlimab Versus Nivolumab Alone After Complete Resection of Stage III-IV Melanoma
Last checked: Nov 19, 2026Latest source record: Jan 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
1,093
Actual
Start
Oct 19, 2021
Primary completion
Dec 16, 2024
Study completion Apr 2, 2025
Sponsor
- Lead sponsor
- Bristol-Myers SquibbBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Aug 12, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess nivolumab plus relatlimab fixed-dose combination (FDC) versus nivolumab alone in participants with completely resected stage III-IV melanoma.
Conditions
- Melanoma
Interventions
NivolumabBiological
Specified dose on specified days
Nivolumab + Relatlimab Fixed Dose CombinationBiological
Specified dose on specified days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Recurrence Free Survival (RFS)Time frame: Approximately 27.5 Months
Locations
184 sites in 25 countries. Site status is shown where the registry gives one.
Local Institution - 0176
Birmingham, Alabama
Local Institution - 0164
Springdale, Arkansas
Local Institution - 0200
Los Angeles, California
Local Institution - 0185
Palo Alto, California
Local Institution - 0162
San Francisco, California
Saint John's Cancer Institute
Santa Monica, California
Local Institution - 0138
Aurora, Colorado
Local Institution - 0166
Washington D.C., District of Columbia
Local Institution - 0243
Miami, Florida
Washington University School Of Medicine
Miami, Florida
Local Institution - 0179
Pensacola, Florida
Moffitt Cancer Center, Richard M. Shulze Family Foundation Outpatient Center
Tampa, Florida
Local Institution - 0191
Atlanta, Georgia
Local Institution - 0148
Atlanta, Georgia
Local Institution - 0202
Chicago, Illinois
Local Institution - 0177
Peoria, Illinois
Local Institution - 0223
Fort Wayne, Indiana
University of Iowa-Holden Comprehensive Cancer Center
Iowa City, Iowa
Local Institution - 0178
Westwood, Kansas
Dana-Farber Cancer Institute-Melanoma
Boston, Massachusetts
Local Institution - 0258
Ann Arbor, Michigan
Local Institution
Grand Rapids, Michigan
Local Institution - 0133
Minneapolis, Minnesota
Local Institution - 0139
Hackensack, New Jersey
Local Institution - 0206
Morristown, New Jersey
Local Institution - 0140
New York, New York
Icahn School Of Medicine At Mount Sinai
New York, New York
Local Institution - 0210
New York, New York
Local Institution - 0130
Charlotte, North Carolina
Local Institution - 0145
Durham, North Carolina
MetroHealth Medical Center
Cleveland, Ohio
Local Institution - 0141
Cleveland, Ohio
The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C
Columbus, Ohio
Local Institution - 0267
Allentown, Pennsylvania
Fox Chase Cancer Center
Philadelphia, Pennsylvania
Local Institution - 0125
Pittsburgh, Pennsylvania
Local Institution - 0171
Charleston, South Carolina
Local Institution - 0147
Germantown, Tennessee
Local Institution - 0183
Nashville, Tennessee
Local Institution - 0146
Austin, Texas
Showing 40 of 184 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.